Message Font: Serif | Sans-Serif
No. of Recommendations: 1
OSI Pharmaceuticals, Genentech and Roche Announce Interim Clinical Data From Phase II Cancer Studies of the Anti-EGFR Therapy Tarceva™ (OSI-774)

--Data In Non-Small Cell Lung and Head and Neck Cancers Presented At The American Society Of Clinical Oncology (ASCO) Meeting--


OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), Genentech, Inc. (NYSE: DNA) and Roche announced today updated findings from two ongoing, Phase II clinical studies of the anti-cancer drug candidate Tarceva™ (OSI-774), an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR). Clinical results presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) demonstrated encouraging anti-cancer activity of Tarceva™ (OSI-774) and its potential utility as a single agent for the treatment of patients with refractory non-small cell lung (NSCLC) and head and neck cancer. The companies also announced that Tarceva™ has been chosen by the alliance as the trademark for OSI-774.

Rest of the article contains details on:

Phase II Non-Small Cell Lung Cancer Trial

Phase II Head and Neck Cancer Trial

Tarceva™ Safety and Tolerability Data

Tarceva™ Comprehensive Clinical Development Program

Read the full article here:

Foolish Regards


Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.